Progyny vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Progyny is a fertility and family building benefits management company providing employer-sponsored fertility coverage that improves outcomes and reduces total fertility spend.
About
Progyny is a publicly traded fertility benefits management company founded in 2008 that has become the leading provider of employer-sponsored fertility benefits in the United States. The company manages fertility coverage for self-insured employers, providing access to a national network of top-tier fertility clinics, a proprietary Smart Cycle benefits design that bundles all medically necessary components of a treatment cycle, and dedicated patient care advocates who guide employees through fertility treatment. Progyny went public on Nasdaq in 2019 under the ticker PGNY and serves over 430 employers covering over 6 million lives including many Fortune 500 companies. The company has published clinical outcomes data demonstrating higher live birth rates, lower multiple birth rates, and lower NICU costs compared to traditional indemnity fertility coverage, translating into healthcare cost savings that offset the benefit cost for employers. Progyny's Smart Cycle design bundles medications, lab tests, and procedures into a single benefit unit that eliminates the piecemeal authorization challenges of traditional insurance coverage. The company competes with Carrot Fertility and Kindbody in the employer fertility benefits market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.